Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
407 "Hepatocellular carcinoma"
Filter
Filter
Article category
Publication year
Reply
Reply to the Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: Surgery vs Ablation: A multicenter retrospective study”
Kazuhiro Nouso, Kazuya Kariyama
Received December 19, 2023  Accepted January 2, 2024  Published online January 19, 2024  
DOI: https://doi.org/10.17998/jlc.2024.01.02    [Accepted]
  • 161 Views
  • 6 Downloads
PDF
Review Article
Complications of immunotherapy in advanced hepatocellular carcinoma
Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Received October 16, 2023  Accepted November 21, 2023  Published online November 29, 2023  
DOI: https://doi.org/10.17998/jlc.2023.11.21    [Accepted]
  • 392 Views
  • 28 Downloads
AbstractAbstract PDF
Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment; however, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period. In this review, we analyzed common irAEs reported in highly cited original articles and systematic reviews. The prevalent adverse reactions include fatigue, pyrexia, rash, pruritus, diarrhea, decreased appetite, nausea, abdominal pain, constipation, hepatitis, and hypothyroidism. Therefore, it is crucial to conduct evaluations not only of gastrointestinal organs but also of cardiac, neurologic, endocrine (including the frequently affected thyroid), and ophthalmic systems before commencing ICIs. This review further explores commonly reported types of irAEs, specific irAEs associated with each ICI agent, rare yet potentially fatal irAEs, and available treatment options for managing them.
Letter to the Editor
Performance of HCC Diagnosis in the KLCA-NCC Guidelines: A Closer Look at MRI Contrast Agents and HCC Imaging Hallmarks
Ji Hye Min, Young Kon Kim
Received September 4, 2023  Accepted October 8, 2023  Published online November 6, 2023  
DOI: https://doi.org/10.17998/jlc.2023.09.27    [Accepted]
  • 336 Views
  • 31 Downloads
PDF
Research Article
Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study
Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Hidenori Toyoda, Toshifumi Tada, Kunihiko Tsuji, Toru Ishikawa, Takeshi Hatanaka, Ei Itobayashi, Koichi Takaguchi, Akemi Tsutsui, Atsushi Naganuma, Satoshi Yasuda, Satoru Kakizaki, Akiko Wakuta, Shohei Shiota, Masatoshi Kudo, Takashi Kumada
Received August 5, 2023  Accepted September 11, 2023  Published online November 6, 2023  
DOI: https://doi.org/10.17998/jlc.2023.09.11    [Epub ahead of print]
  • 522 Views
  • 67 Downloads
AbstractAbstract PDF
Background/Aim
The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database.
Methods
The study included consecutive 2,067 patients with solitary HCC who were treated with either ablation (n=1,248) or surgery (n=819). Th e patients were divided into three groups based on the tumor size and compared the outcomes of the two therapies using propensity score matching.
Results
No significant difference in recurrence-free survival (RFS) or overall survival (OS) was found between surgery and ablation groups for tumors measuring ≤2 cm or >2 cm but ≤3 cm. For tumors measuring >3 cm but ≤5 cm, RFS was significantly better with surgery than with ablation (3.6 and 2.0 years, respectively, P=0.0297). However, no significant difference in OS was found between surgery and ablation in this group (6.7 and 6.0 years, respectively, P=0.668).
Conclusion
The study suggests that surgery and ablation can be equally used as a treatment for solitary HCC no more than 3 cm in diameter. For HCCs measuring 3-5 cm, the OS was not different between therapies; thus, ablation and less invasive therapy can be considered a treatment option; however, special caution should be taken to prevent recurrence.
Case Reports
Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
Yong Tae Kim, Jina Kim, Jinsil Seong
J Liver Cancer. 2023;23(1):225-229.   Published online March 16, 2023
DOI: https://doi.org/10.17998/jlc.2023.02.27
  • 902 Views
  • 67 Downloads
  • 2 Citations
AbstractAbstract PDF
Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While the results are encouraging, more than half of patients with advanced HCC are still being treated in a palliative setting. Radiotherapy (RT) is known to induce immunogenic effects that may enhance the therapeutic efficacy of immune checkpoint inhibitors. Herein, we report the case of a patient with advanced HCC with massive portal vein tumor thrombosis treated with a combination of RT and AteBeva, who showed near complete response in tumor thrombosis and favorable response to HCC. Although this is a rare case, it shows the importance of reducing the tumor burden via RT to combination immunotherapy in patients with advanced HCC.

Citations

Citations to this article as recorded by  
  • Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tae Hyun Kim, Bo Hyun Kim, Yu Ri Cho, Young-Hwan Koh, Joong-Won Park
    Journal of Liver Cancer.2023; 23(2): 330.     CrossRef
  • Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
    Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
    Clinical and Molecular Hepatology.2023; 29(4): 945.     CrossRef
A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
Yuri Cho, Bo Hyun Kim, Tae Hyun Kim, Young Hwan Koh, Joong-Won Park
J Liver Cancer. 2023;23(1):206-212.   Published online February 24, 2023
DOI: https://doi.org/10.17998/jlc.2023.02.09
  • 1,211 Views
  • 58 Downloads
  • 1 Citation
AbstractAbstract PDF
Peritoneal seeding of hepatocellular carcinoma (HCC) is incurable and has poor prognosis. A 68-year-old man underwent surgical resection for a 3.5 cm single nodular HCC at the tip of segment 3 and transarterial chemoembolization for a 1.5 cm-sized recurrent HCC at the tip of segment 6. 3 months later, an increasing 1 cm pelvic nodule on the rectovesical pouch warranted radiotherapy. Although it stabilized, a new 2.7 cm-sized peritoneal nodule in the right upper quadrant (RUQ) omentum appeared 3.5 years after radiotherapy. Hence, omental mass and small bowel mesentery mass excision were performed. 3 years later, recurrent peritoneal metastases in the RUQ omentum and rectovesical pouch progressed. 33 cycles of atezolizumab and bevacizumab treatment elicited stable disease response. Finally, laparoscopic left pelvic peritonectomy was performed without tumor recurrence. Herein, we present a case of HCC with peritoneal seeding that was successfully treated with surgery after radiotherapy and systemic therapy, leading to complete remission.

Citations

Citations to this article as recorded by  
  • Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tae Hyun Kim, Bo Hyun Kim, Yu Ri Cho, Young-Hwan Koh, Joong-Won Park
    Journal of Liver Cancer.2023; 23(2): 330.     CrossRef
Original Article
Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria
Ja Kyung Yoon, Sunyoung Lee, Jeong Ah Hwang, Ji Eun Lee, Seung-seob Kim, Myeong-Jin Kim
J Liver Cancer. 2023;23(1):157-165.   Published online February 23, 2023
DOI: https://doi.org/10.17998/jlc.2023.02.07
  • 1,371 Views
  • 83 Downloads
  • 1 Citation
AbstractAbstract PDFSupplementary Material
Background/Aim
This study aimed to determine the diagnostic performance of 2022 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) imaging criteria compared with the 2018 KLCA-NCC for hepatocellular carcinoma (HCC) in high-risk patients using magnetic resonance imaging (MRI).
Methods
This retrospective study included 415 treatment-naïve patients (152 patients who underwent extracellular contrast agent [ECA]-MRI and 263 who underwent hepatobiliary agent [HBA]-MRI; 535 lesions, including 412 HCCs) with a high risk of HCC who underwent contrast-enhanced MRI. Two readers evaluated all lesions according to the 2018 and 2022 KLCA-NCC imaging diagnostic criteria, and the per-lesion diagnostic performances were compared.
Results
In “definite” HCC category of both 2018 and 2022 KLCA-NCC, HBA-MRI showed a significantly higher sensitivity for the diagnosis of HCC than ECA-MRI (77.0% vs. 64.3%, P=0.006) without a significant difference in specificity (94.7% vs. 95.7%, P=0.801). On ECAMRI, “definite” or “probable” HCC categories of the 2022 KLCA-NCC had significantly higher sensitivity than those of the 2018 KLCA-NCC (85.3% vs. 78.3%, P=0.002) with identical specificity (93.6%). On HBA-MRI, the sensitivity and specificity of “definite” or “probable” HCC categories of both 2018 and 2022 KLCA-NCC were not significantly different (83.3% vs. 83.6%, P>0.999 and 92.1% vs. 90.8%, P>0.999, respectively).
Conclusions
In “definite” HCC category of both 2018 and 2022 KLCA-NCC, HBA-MRI provides better sensitivity than ECA-MRI without compromising specificity. On ECA-MRI, “definite” or “probable” HCC categories of the 2022 KLCA-NCC may improve sensitivity in the diagnosis of HCC compared with the 2018 KLCA-NCC.

Citations

Citations to this article as recorded by  
  • Impact of the updated KLCA-NCC criteria for diagnosis of “probable HCC” in liver MRI: comparisons between KLCA v2022 and v2018
    Jeong Hee Yoon
    Journal of Liver Cancer.2023; 23(1): 124.     CrossRef
Guideline
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
J Liver Cancer. 2023;23(1):1-120.   Published online December 9, 2022
DOI: https://doi.org/10.17998/jlc.2022.11.07
  • 6,357 Views
  • 252 Downloads
  • 22 Citations
AbstractAbstract PDF
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

Citations

Citations to this article as recorded by  
  • Contrast-enhanced US for HCC: Finally out from the waiting list?
    Richard G. Barr, Luigi Bolondi
    Hepatology.2024; 79(2): 267.     CrossRef
  • The Epidemiology of Hepatitis B Virus Infection in Korea: 15-Year Analysis
    Log Young Kim, Jeong-Ju Yoo, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Dong Hyeon Lee, Jae Young Jang
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study
    Sujeong Shin, Won Sohn, Yoosoo Chang, Yoosun Cho, Min‐Jung Kwon, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
    Hepatology Research.2024;[Epub]     CrossRef
  • Research Progress of lncRNA-ATB/miR-141-3p/GP73 Ax-is-Mediated EMT Promoting TACE Refractoriness
    棋 耿
    Advances in Clinical Medicine.2024; 14(01): 903.     CrossRef
  • Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC
    Jiwon Yang, Jonggi Choi, Won‐Mook Choi, Kang Mo Kim, Han Chu Lee, Ju Hyun Shim
    Liver International.2024;[Epub]     CrossRef
  • Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma
    Jun Il Kim, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park, Jeong-Ju Yoo
    Digestive Diseases and Sciences.2024;[Epub]     CrossRef
  • Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria
    Ja Kyung Yoon, Sunyoung Lee, Jeong Ah Hwang, Ji Eun Lee, Seung-seob Kim, Myeong-Jin Kim
    Journal of Liver Cancer.2023; 23(1): 157.     CrossRef
  • Radiologic features of hepatocellular carcinoma related to prognosis
    Shin Hye Hwang, Hyungjin Rhee
    Journal of Liver Cancer.2023; 23(1): 143.     CrossRef
  • Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
    Sun Hong Yoo, Soon Sun Kim, Sang Gyune Kim, Jung Hyun Kwon, Han-Ah Lee, Yeon Seok Seo, Young Kul Jung, Hyung Joon Yim, Do Seon Song, Seong Hee Kang, Moon Young Kim, Young-Hwan Ahn, Jieun Han, Young Seok Kim, Young Chang, Soung Won Jeong, Jae Young Jang, J
    Journal of Liver Cancer.2023; 23(1): 189.     CrossRef
  • Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease
    Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon
    Journal of Clinical Medicine.2023; 12(9): 3336.     CrossRef
  • Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association
    Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim
    Korean Journal of Radiology.2023; 24(7): 606.     CrossRef
  • Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association
    Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim
    Journal of Liver Cancer.2023; 23(2): 241.     CrossRef
  • Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association
    Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim
    Clinical and Molecular Hepatology.2023; 29(3): 521.     CrossRef
  • Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
    Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(3): 733.     CrossRef
  • A nationwide study on the current treatment status and natural prognosis of hepatocellular carcinoma in elderly
    Jeong-Ju Yoo, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park
    Scientific Reports.2023;[Epub]     CrossRef
  • Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review
    Woo Kyoung Jeong
    Journal of Liver Cancer.2023; 23(2): 272.     CrossRef
  • The Current Evidence of Intensity-Modulated Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Won Il Jang, Sunmi Jo, Ji Eun Moon, Sun Hyun Bae, Hee Chul Park
    Cancers.2023; 15(20): 4914.     CrossRef
  • Clinical outcome of surgical resection for multifocal T2-T3 hepatocellular carcinoma up to 3 nodules: a comparative analysis with a single nodule
    Sehyeon Yu, Hye-Sung Jo, Young-Dong Yu, Yoo jin Choi, Dong-Sik Kim
    Journal of Liver Cancer.2023; 23(2): 377.     CrossRef
  • Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma: strengths and shortcomings
    Sung Won Lee, Min Kyu Kang, Xiang Zhang
    Journal of Liver Cancer.2023; 23(2): 238.     CrossRef
  • Sequential regorafenib or nivolumab therapy in recurrent hepatocellular carcinoma with sorafenib failure in liver transplant patients does not improve prognosis
    Jieun Kwon, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
    Annals of Liver Transplantation.2023; 3(2): 104.     CrossRef
  • Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase 2 study
    Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
    JHEP Reports.2023; : 100991.     CrossRef
  • Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area
    Joo Hyun Oh, Jonghyun Lee, Eileen L. Yoon, Soung Won Jeong, Soon Sun Kim, Young Eun Chon, Sang Bong Ahn, Dae Won Jun
    Cancers.2023; 16(1): 150.     CrossRef
Review Article
Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma
Eun-Ji Choi, Young-Joon Kim
J Liver Cancer. 2022;22(2):103-114.   Published online September 22, 2022
DOI: https://doi.org/10.17998/jlc.2022.09.08
  • 3,111 Views
  • 135 Downloads
  • 3 Citations
AbstractAbstract PDFSupplementary Material
Advances in our knowledge of the molecular characteristics of hepatocellular carcinoma (HCC) have enabled significant progress in the detection and therapeutic prediction of HCC. As a non-invasive alternative to tissue biopsy, liquid biopsy examines circulating cellular components such as exosomes, nucleic acids, and cell-free DNA found in body fluids (e.g., urine, saliva, ascites, and pleural effusions) and provides information about tumor characteristics. Technical advances in liquid biopsy have led to the increasing adoption of diagnostic and monitoring applications for HCC. This review summarizes the various analytes, ongoing clinical trials, and case studies of United States Food and Drug Administrationapproved in vitro diagnostic applications for liquid biopsy, and provides insight into its implementation in managing HCC.

Citations

Citations to this article as recorded by  
  • Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
    Sun Hong Yoo, Soon Sun Kim, Sang Gyune Kim, Jung Hyun Kwon, Han-Ah Lee, Yeon Seok Seo, Young Kul Jung, Hyung Joon Yim, Do Seon Song, Seong Hee Kang, Moon Young Kim, Young-Hwan Ahn, Jieun Han, Young Seok Kim, Young Chang, Soung Won Jeong, Jae Young Jang, J
    Journal of Liver Cancer.2023; 23(1): 189.     CrossRef
  • Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
    Jeong-Ju Yoo, Sang Gyune Kim
    Clinical and Molecular Hepatology.2023; 29(2): 513.     CrossRef
  • Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer
    Chau-Ming Kan, Xiao Meng Pei, Martin Ho Yin Yeung, Nana Jin, Simon Siu Man Ng, Hin Fung Tsang, William Chi Shing Cho, Aldrin Kay-Yuen Yim, Allen Chi-Shing Yu, Sze Chuen Cesar Wong
    International Journal of Molecular Sciences.2023; 24(13): 11026.     CrossRef
Case Report
Fibrolamellar hepatocellular carcinoma that was successfully treated with surgical resection: a case report
Seong Kyun Na
J Liver Cancer. 2022;22(2):178-182.   Published online June 22, 2022
DOI: https://doi.org/10.17998/jlc.2022.06.10
  • 1,816 Views
  • 60 Downloads
AbstractAbstract PDF
Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare malignant hepatic cancer with characteristics that differ from those of typical hepatocellular carcinoma (HCC). Unlike conventional HCC, FLHCC is common in young patients without any underlying liver disease and is known to be associated with a unique gene mutation. This cancer type is rare in Asia, with only a few cases being reported in Korea. We report a case of FLHCC in a young woman that successfully underwent surgical resection. The efficacy of alternative treatments, such as transarterial chemoembolization or systemic chemotherapies, has not yet been established. To conclude, early diagnosis and appropriate surgical resection are important for the treatment of FLHCC.
Review Article
Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma
Dong-Hyun Kim
J Liver Cancer. 2022;22(2):93-102.   Published online April 22, 2022
DOI: https://doi.org/10.17998/jlc.2022.03.28
  • 4,758 Views
  • 161 Downloads
  • 5 Citations
AbstractAbstract PDF
Interventional oncology (IO) local therapies of hepatocellular carcinoma (HCC) can activate anti-cancer immunity and it is potentially leading to an anti-cancer immunity throughout the body. For the development of an effective HCC treatment regime, great emphasis has been dedicated to different IO local therapy mediated immune modulation and possible combinations with immune checkpoint inhibitor immunotherapy. In this review paper, we summarize the status of combination of IO local therapy and immunotherapy, as well as the prospective role of therapeutic carriers and locally administered immunotherapy in advanced HCC.

Citations

Citations to this article as recorded by  
  • Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports
    Kyeong-Min Yeom, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Medicina.2024; 60(1): 157.     CrossRef
  • Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment
    Bongseo Choi, Jason Pe, Bo Yu, Dong-Hyun Kim
    Cancers.2023; 15(3): 913.     CrossRef
  • Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo‐Immuno‐Embolization for the Treatment of Hepatocellular Carcinoma
    Heegon Kim, Bongseo Choi, Samdeep K. Mouli, Hyunjun Choi, Kathleen R. Harris, Laura M. Kulik, Robert J. Lewandowski, Dong‐Hyun Kim
    Advanced Healthcare Materials.2023;[Epub]     CrossRef
  • The Current Evidence of Intensity-Modulated Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Won Il Jang, Sunmi Jo, Ji Eun Moon, Sun Hyun Bae, Hee Chul Park
    Cancers.2023; 15(20): 4914.     CrossRef
  • Inducing the Abscopal Effect in Liver Cancer Treatment: The Impact of Microwave Ablation Power Levels and PD-1 Antibody Therapy
    Changli Liao, Guiyuan Zhang, Ruotong Huang, Linyuan Zeng, Bin Chen, Haitao Dai, Keyu Tang, Run Lin, Yonghui Huang
    Pharmaceuticals.2023; 16(12): 1672.     CrossRef
Case Report
Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report
Min Kyung Park, Su Jong Yu
J Liver Cancer. 2022;22(1):69-74.   Published online March 21, 2022
DOI: https://doi.org/10.17998/jlc.2022.03.09
  • 3,065 Views
  • 103 Downloads
  • 3 Citations
AbstractAbstract PDF
Treatment options for advanced hepatocellular carcinoma (HCC) have been rapidly evolving. Herein, we describe a patient with advanced HCC and portal vein tumor thrombosis (PVTT) who responded decisively to a multidisciplinary approach. The patient had an ill-defined infiltrative HCC (diffuse subtype), with several intrahepatic metastasis and tumor invasion of left portal vein. Concurrent use of transarterial radioembolization (TARE) and systemic therapeutics (atezolizumab + bevacizumab) ultimately proved successful. There was marked reduction in tumor volume after TARE and an additional three cycles of atezolizumab plus bevacizumab. This concurrent treatment was well tolerated, without adverse events during immunotherapy. The impressive results achieved suggest that concurrent TARE and combination atezolizumab/bevacizumab is a promising treatment approach for advanced HCC with PVTT.

Citations

Citations to this article as recorded by  
  • Combining immunotherapy with transarterial radioembolization
    ZeynepCeren Balaban Genc, Efe Soydemır, SevalAy Ersoy, Tunc Ones
    Indian Journal of Nuclear Medicine.2023; 38(2): 145.     CrossRef
  • The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
    Maria Cerreto, Ferdinando Cardone, Lucia Cerrito, Leonardo Stella, Francesco Santopaolo, Maria Pallozzi, Antonio Gasbarrini, Francesca Romana Ponziani
    Current Oncology.2023; 30(10): 8774.     CrossRef
  • Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?
    Won Hyeok Choe
    Journal of Liver Cancer.2022; 22(1): 1.     CrossRef
Original Article
Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma
Jeong Won Jang, Ji Min Kim, Hye Seon Kim, Jin Seoub Kim, Ji Won Han, Soon Kyu Lee, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
J Liver Cancer. 2022;22(1):30-39.   Published online March 21, 2022
DOI: https://doi.org/10.17998/jlc.2022.02.25
  • 3,447 Views
  • 125 Downloads
AbstractAbstract PDFSupplementary Material
Background/Aim
Hepatocellular carcinoma (HCC) is associated with poor prognosis, largely due to late detection. Highly accurate biomarkers are urgently needed to detect early-stage HCC. Our study aims to explore the diagnostic performance of serum exosomal microRNA (miR)-720 in HCC.
Methods
Exosomal miRNA was measured via quantitative real-time PCR. A correlation analysis of exosomal miR-720 and tumor or clinico-demographic data of patients with HCC was performed. The receiver operating characteristic (ROC) curve was used to assess the diagnostic capacity of serum exosomal miR-720 for HCC, in comparison with α-fetoprotein (AFP) and prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II).
Results
MiR-720 was chosen as a potential HCC marker via miR microarray based on significant differential expression between tumor and non-tumor samples. Serum exosomal miR-720 was significantly upregulated in patients with HCC (n=114) versus other liver diseases (control, n=30), with a higher area under the ROC curve (AUC=0.931) than the other markers. Particularly, serum exosomal miR-720 showed superior performance in diagnosing small HCC (< 5 cm; AUC=0.930) compared with AFP (AUC=0.802) or PIVKA-II (AUC=0.718). Exosomal miR-720 levels showed marginal correlation with tumor size. The proportion of elevated miR-720 also increased with intrahepatic tumor stage progression. Unlike AFP or PIVKA-II showing a significant correlation with aminotransferase levels, the exosomal miR-720 level was not affected by aminotransferase levels.
Conclusions
Serum exosomal miR-720 is an excellent biomarker for the diagnosis of HCC, with better performance than AFP or PIVKA-II. Its diagnostic utility is maintained even in small HCC and is unaffected by aminotransferase levels.
Case Report
Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
Ahlim Lee, Jaejun Lee, Hyun Yang, Soo-Yoon Sung, Chang Ho Jeon, Su Ho Kim, Moon Hyung Choi, Young Joon Lee, Ho Jong Chun, Si Hyun Bae
J Liver Cancer. 2022;22(1):75-83.   Published online March 18, 2022
DOI: https://doi.org/10.17998/jlc.2022.03.04
  • 3,597 Views
  • 89 Downloads
  • 2 Citations
AbstractAbstract PDF
Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therapeutic outcomes were unsatisfactory in more than half of the patients. Accordingly, many ongoing trials combine conventional modalities with new drugs such as immune checkpoint inhibitors for better treatment outcomes, and they are expected to benefit patients with limited responses to conventional treatment. Here, two patients with advanced stage HCC with preserved liver function and good performance status showed partial response after treatment with combination or sequential therapy of AteBeva, hepatic arterial infusion chemotherapy, radiation therapy, and transarterial chemoembolization. These findings indicate the efficacy of multidisciplinary treatment against advanced HCC. Additional studies are required to establish optimal treatment strategies.

Citations

Citations to this article as recorded by  
  • Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tae Hyun Kim, Bo Hyun Kim, Yu Ri Cho, Young-Hwan Koh, Joong-Won Park
    Journal of Liver Cancer.2023; 23(2): 330.     CrossRef
  • Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?
    Won Hyeok Choe
    Journal of Liver Cancer.2022; 22(1): 1.     CrossRef
Review Article
Radioembolization for hepatocellular carcinoma: what clinicians need to know
Jin Woo Choi, Hyo-Cheol Kim
J Liver Cancer. 2022;22(1):4-13.   Published online February 23, 2022
DOI: https://doi.org/10.17998/jlc.2022.01.16
  • 6,419 Views
  • 374 Downloads
  • 5 Citations
AbstractAbstract PDF
Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of 90Y radioactive microspheres available, namely, glass and resin microspheres, with comparable clinical outcomes. In general, TARE outperforms transarterial chemoembolization regarding post-embolization syndrome, time to progression, tumor downsizing for liver transplantation, and hospitalization stay. Although TARE is commonly recommended for patients with unresectable large HCCs, it can be an alternative to or performed in combination with ablation, surgical resection, and systemic treatment. This review aimed to address 90Y radioactive microspheres, patient selection, clinical outcomes, simulation tests, radioembolization procedures, follow-up imaging, and complications.

Citations

Citations to this article as recorded by  
  • Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
    Sung Won Chung, Heejin Cho, Hyunjae Shin, Jeayeon Park, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Myungsu Lee, Yoon Jun Kim, Jin Chul Paeng, Jung-Hwan Yoon, Jin Wook Chung, Jeong-Hoon Lee, Hyo-Cheol Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review
    Brandon M. Meyers, Jennifer J. Knox, David M. Liu, Deanna McLeod, Ravi Ramjeesingh, Vincent C. Tam, Howard J. Lim
    Cancer Treatment Reviews.2023; 118: 102584.     CrossRef
  • Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors
    Cody R. Criss, Mina S. Makary
    Biology.2023; 12(7): 999.     CrossRef
  • Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region
    Imam Waked, Sherif Alsammany, Sayed Hammad Tirmazy, Kakil Rasul, Jafar Bani‐Issa, Wael Abdel‐Razek, Ashraf Omar, Amr Shafik, Salem Eid, Amr Abdelaal, Ahmed Hosni, Gamal Esmat
    Liver International.2023; 43(10): 2062.     CrossRef
  • Impact of Low Skeletal Muscle Mass on Long-Term Outcomes in Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization: A Retrospective Multi-Center Study
    Heechul Nam, Hyun Yang, Ho Soo Chun, Han Ah Lee, Joon Yeul Nam, Jeong Won Jang, Yeon Seok Seo, Do Young Kim, Yoon Jun Kim, Si Hyun Bae
    Cancers.2023; 15(21): 5195.     CrossRef

JLC : Journal of Liver Cancer